Deploying the full transcriptome using RNA sequencing. Jo Vandesompele, CSO and co-founder The Non-Coding Genome May 12, 2016, Leuven
|
|
- Esmond Goodwin
- 6 years ago
- Views:
Transcription
1 Deploying the full transcriptome using RNA sequencing Jo Vandesompele, CSO and co-founder The Non-Coding Genome May 12, 2016, Leuven
2 Roadmap Biogazelle the power of RNA reasons to study non-coding RNA tech development and tools for ncrna sequencing reference transcriptome abundant small RNA depletion from biofluids functional annotation of long non-coding RNAs
3 Biogazelle research & development stage biotech company deploying the power of RNA for next generation diagnostics and therapeutics in the field of oncology internal R&D programs service / co-development for customers / partners focus on non-coding RNA focus on clinically relevant samples
4 RNA the movie DNA a picture
5 The power of RNA dynamic nature (time, location and condition specific) diverse different types: messenger, micro, long non-coding, transfer, ribosomal, etc. varying abundance levels: 1 copy/cell > 100,000 copies/cell structural differences: splicing, isoforms, fusion, mutations measurement technologies are ready (discovery - validation) same transcript can be biomarker and therapeutic target rational drug design
6 RNA is the new DNA Nature Reviews Genetics, 2016
7 microrna profiling in biofluids RNA equivalent of µl biofluid good reproducibility and sensitivity
8 Total RNA sequencing on FFPE excellent concordance with mrna capture sequencing good sensitivity for detecting differentially expressed lncrnas fo ld c ha ng e (lo g 2) a c c ord ing to m RNA c a p ture se q ue nc ing g e ne c o unt lncrna mrna fo ld c ha ng e (lo g 2) a c c ord ing to to ta l RNA se q ue nc ing 0 a ve ra g e d e te c te d d iffe re ntia lly e xp re sse d
9 Total RNA sequencing on FFPE excellent concordance with mrna capture sequencing good sensitivity for detecting differentially expressed lncrnas MYC lncrna AC tumor normal
10 Pioneers in the ncrna field 2010 mirna expression profiling (768) qpcr platform to measure 1718 lncrnas 2012 custom microarray 20,000 lncrnas EU FP7 SysKid & MIAMI, 1000 s samples today qpcr assays for entire LNCipedia Integrated DNA Technologies (IDT) will bring lncrna PrimeTime qpcr assays to the market total RNA and small RNA sequencing
11 Six reasons to look at the non-coding genome 1. Non-coding RNAs are master regulators of gene expression, in health and disease
12 Six reasons to look at the non-coding genome 1. Non-coding RNAs are master regulators of gene expression, in health and disease 2. Growing evidence for the potential of non-coding RNAs as excellent biomarkers % % mrna microrna lncrna
13 Six reasons to look at the non-coding genome 1. Non-coding RNAs are master regulators of gene expression, in health and disease 2. Growing evidence for the potential of non-coding RNAs as excellent biomarkers 3. Attractive intellectual property landscape
14 Six reasons to look at the non-coding genome 1. Non-coding RNAs are master regulators of gene expression, in health and disease 2. Growing evidence for the potential of non-coding RNAs as excellent biomarkers 3. Attractive intellectual property landscape 4. Tissue and disease specific non-coding RNA expression patterns
15 Six reasons to look at the non-coding genome 1. Non-coding RNAs are master regulators of gene expression, in health and disease 2. Growing evidence for the potential of non-coding RNAs as excellent biomarkers 3. Attractive intellectual property landscape 4. Tissue and disease specific non-coding RNA expression patterns 5. Increase the chances of finding robust biomarker signatures
16 Total RNA seq doubles the number of differentially expressed genes mrna pond total RNA pond
17 Total RNA sequencing identifies RNAs in circulation top 5 genes lnc-irs4-2 lnc-tpte-3 lnc-tmem132c-11 lnc-linc lnc-lrr1-1 Biogazelle collaboration with Illumina to optimize workflows on liquid biopsies
18 Six reasons to look at the non-coding genome 1. Non-coding RNAs are master regulators of gene expression, in health and disease 2. Growing evidence for the potential of non-coding RNAs as excellent biomarkers 3. Attractive intellectual property landscape 4. Tissue and disease specific non-coding RNA expression patterns 5. Increase the chances of finding robust biomarker signatures 6. Excellent therapeutic targets for RNA-targeting therapies
19 Leucci et al., Nature, 2016 only expressed in malignant melanoma, not in melanocytes nor any other cell type antisense mediated knockdown kills melanoma cells in vitro and in vivo important role in mitochondrial biogenesis
20
21 Unified reference transcriptome for transcript annotation mrna small ncrna lncrna pseudogenes lncrna
22 Unified reference transcriptome for transcript annotation remove redundant gene models for accurate gene/transcript level quantification deal with noisy data sources (e.g. intron-retention transcripts from NONCODE) maintain links to both Ensembl and LNCipedia result is a unique and rich annotation resource
23
24 Murine serum samples phase I Good quality data but very low abundance of mirna reads
25 Murine serum samples phase I On average only 169 mirnas detected Most reads are consumed by trnas
26 trna fragment depletion (phase II) 11 biotin-labeled DNA probes designed based on most abundant sequences of phase I samples (trna-glu, trna-gly, trna-his) Good quality data and higher mirna fraction
27 trna fragment depletion (phase II) trnas (trna-glu, trna-gly, trna-his) successfully removed On average 450 mirnas are detected Still many reads consumed by trna fragments New trna fragments emerge as abundant (trna-val, trna- Met)
28 trna fragment depletion with more probes (phase III) 16 probes designed based on most abundant sequences of phase 1+2 samples (trna-glu, trna-gly, trna-his, trna-val, trna-met) On average 570 mirnas detected (50 µl serum equivalent) Most reads align to mirnas
29 Depletion comparisons phase I phase II phase III probes: avg mirnas: trna %: 53.44% 40.09% 3.88% mirna %: 1.12% 19.41% 28.33% successful depletion from tiny volumes of biofluids others, e.g. Y-RNAs in human plasma
30
31 Therapeutic target selection 126 primary samples (normal and tumors) (9B reads) colon liver lung breast, ovarian, melanoma, bladder, prostate, kidney T N T N T N T N cancer perturbation experiments 180 in vitro perturbations (9B reads) total RNA sequencing public tumor RNA sequencing data (The Cancer Genome Atlas) total RNA sequencing complete lncrnome (polya+ and polya-) polya+ lncrnome complete lncrnome (polya+ and polya-) mrna lncrna guilt-by-association tumor > normal cancer specific lncrnas primary selection criteria predicted function in proliferation and survival pathways (LNCarta) copy number variation / GWAS / cancer gene proximity secondary selection criteria screening cell line transcriptome filter (total RNA sequencing) lncrna targets
32 Example of colon cancer specific lncrna
33 LNCarta database of lncrna functions
34 Identifying candidate therapeutic lncrnas LNCarta o CELL CYCLE o APOPTOSIS o PROLIFERATION o lncrna expression o tumor vs normal o colon, liver, lung therapeutic lncrnas for experimental validation
35 LNCarta workflow identifies known oncogenic lncrnas CRNDE CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mtor signaling BCYRN1 BCYRN1, a c-myc-activated long non-coding RNA, regulates cell metastasis of non-small-cell lung cancer HOX-AS2 Long noncoding RNA HOXA-AS2 promotes gastric cancer proliferation by epigenetically silencing P21/PLK3/DDIT3 expression. HOX antisense lincrna HOXA AS2 is an apoptosis repressor in all-trans retinoic acid treated NB4 promyelocytic leukemia cells ZFAS1 Amplification of long noncoding RNA ZFAS1 promotes metastasis in hepatocellular carcinoma Up-regulated expression of long non-coding RNA ZFAS1 associates with aggressive tumor progression and poor prognosis in gastric cancer patients
36 Biogazelle s RNA targeting therapeutics programs RNA target discovery RNA target validation drug optimization clinical validation BGZ-Tx1 LUNG BGZ-Tx2 LIVER BGZ-Tx3 COLON 3 cancer types 300 lncrna targets antisense molecules lung cancer liver cancer colon cancer
37 Take home message non-coding RNA has great potential biomarker, mode of action, disease mechanism Biogazelle has developed optimized RNA sequencing tools clinically relevant samples (low input, fragmented RNA) depletion of unwanted highly abundant small RNAs unified reference transcriptome LNCarta database of predicted lncrna functions to speed up downstream analyses
38 Acknowledgements Alan Van Goethem Pieter-Jan Volders Pieter Mestdagh Thomas Piofczyk Nele Nijs Carolina Fierro Manuel Luypaert Anneleen Beckers Gert Van Peer Ariane De Ganck Jan Hellemans
Genomic explorations have offered us a great deal. Buried Treasure
18 Buried Treasure Noncoding DNA makes up the majority of our genomes, much of it being conserved and transcribed. Though the functions of small regulatory RNA molecules are well known, what about so-called
More informationRNA capture sequencing enabled liquid biopsy screening
RNA capture sequencing enabled liquid biopsy screening Jo Vandesompele, Biogazelle CSO LKI symposium Liquid Biopsies & Cancer Leuven, Belgium, August 30, 2017 2017 Biogazelle. All rights reserved. 1 Acknowledgements
More informationgenomics for systems biology / ISB2020 RNA sequencing (RNA-seq)
RNA sequencing (RNA-seq) Module Outline MO 13-Mar-2017 RNA sequencing: Introduction 1 WE 15-Mar-2017 RNA sequencing: Introduction 2 MO 20-Mar-2017 Paper: PMID 25954002: Human genomics. The human transcriptome
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationEPIGENOMICS PROFILING SERVICES
EPIGENOMICS PROFILING SERVICES Chromatin analysis DNA methylation analysis RNA-seq analysis Diagenode helps you uncover the mysteries of epigenetics PAGE 3 Integrative epigenomics analysis DNA methylation
More informationSelective depletion of abundant RNAs to enable transcriptome analysis of lowinput and highly-degraded RNA from FFPE breast cancer samples
DNA CLONING DNA AMPLIFICATION & PCR EPIGENETICS RNA ANALYSIS Selective depletion of abundant RNAs to enable transcriptome analysis of lowinput and highly-degraded RNA from FFPE breast cancer samples LIBRARY
More informationProfiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola
Profiles of gene expression & diagnosis/prognosis of cancer MCs in Advanced Genetics Ainoa Planas Riverola Gene expression profiles Gene expression profiling Used in molecular biology, it measures the
More informationMicroRNA in Cancer Karen Dybkær 2013
MicroRNA in Cancer Karen Dybkær RNA Ribonucleic acid Types -Coding: messenger RNA (mrna) coding for proteins -Non-coding regulating protein formation Ribosomal RNA (rrna) Transfer RNA (trna) Small nuclear
More informationAnalysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
More informationSimple, rapid, and reliable RNA sequencing
Simple, rapid, and reliable RNA sequencing RNA sequencing applications RNA sequencing provides fundamental insights into how genomes are organized and regulated, giving us valuable information about the
More informationScreening for novel oncology biomarker panels using both DNA and protein microarrays. John Anson, PhD VP Biomarker Discovery
Screening for novel oncology biomarker panels using both DNA and protein microarrays John Anson, PhD VP Biomarker Discovery Outline of presentation Introduction to OGT and our approach to biomarker studies
More informationmicrorna Presented for: Presented by: Date:
microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions
More informationRNA-seq Introduction
RNA-seq Introduction DNA is the same in all cells but which RNAs that is present is different in all cells There is a wide variety of different functional RNAs Which RNAs (and sometimes then translated
More informationmirna Dr. S Hosseini-Asl
mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region
More informationRNA SEQUENCING AND DATA ANALYSIS
RNA SEQUENCING AND DATA ANALYSIS Length of mrna transcripts in the human genome 5,000 5,000 4,000 3,000 2,000 4,000 1,000 0 0 200 400 600 800 3,000 2,000 1,000 0 0 2,000 4,000 6,000 8,000 10,000 Length
More informationFrom reference genes to global mean normalization
From reference genes to global mean normalization Jo Vandesompele professor, Ghent University co-founder and CEO, Biogazelle qpcr Symposium USA November 9, 2009 Millbrae, CA outline what is normalization
More informationA novel and universal method for microrna RT-qPCR data normalization
A novel and universal method for microrna RT-qPCR data normalization Jo Vandesompele professor, Ghent University co-founder and CEO, Biogazelle 4 th International qpcr Symposium Weihenstephan, March 1,
More informationA complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis
APPLICATION NOTE Cell-Free DNA Isolation Kit A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis Abstract Circulating cell-free DNA (cfdna) has been shown
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationRegulation of Gene Expression in Eukaryotes
Ch. 19 Regulation of Gene Expression in Eukaryotes BIOL 222 Differential Gene Expression in Eukaryotes Signal Cells in a multicellular eukaryotic organism genetically identical differential gene expression
More informationRECENT ADVANCES IN THE MOLECULAR DIAGNOSIS OF BREAST CANCER
Technology Transfer in Diagnostic Pathology. 6th Central European Regional Meeting. Cytopathology. Balatonfüred, Hungary, April 7-9, 2011. RECENT ADVANCES IN THE MOLECULAR DIAGNOSIS OF BREAST CANCER Philippe
More informationQIAGEN Complete Solutions for Liquid Biopsy Molecular Testing
QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More informationA two-microrna signature in urinary exosomes for diagnosis of prostate cancer
Poster # B4 A two-microrna signature in urinary exosomes for diagnosis of prostate cancer Anne Karin Ildor Rasmussen 1, Peter Mouritzen 1, Karina Dalsgaard Sørensen 3, Thorarinn Blondal 1, Jörg Krummheuer
More informationIso-Seq Method Updates and Target Enrichment Without Amplification for SMRT Sequencing
Iso-Seq Method Updates and Target Enrichment Without Amplification for SMRT Sequencing PacBio Americas User Group Meeting Sample Prep Workshop June.27.2017 Tyson Clark, Ph.D. For Research Use Only. Not
More informationCircular RNAs (circrnas) act a stable mirna sponges
Circular RNAs (circrnas) act a stable mirna sponges cernas compete for mirnas Ancestal mrna (+3 UTR) Pseudogene RNA (+3 UTR homolgy region) The model holds true for all RNAs that share a mirna binding
More informationThe Cancer Genome Atlas
The Cancer Genome Atlas July 14, 2011 Kenna M. Shaw, Ph.D. Deputy Director The Cancer Genome Atlas Program TCGA: Core Objectives Launched in 2006 as a pilot and expanded in 2009, the goals of TCGA are
More informationExploiting extracellular body fluid RNA for precision medicine purposes
Exploiting extracellular body fluid RNA for precision medicine purposes Jo Vandesompele, Biogazelle CSO Precision LBx Summit San Diego, USA, January 30, 2018 2018 Biogazelle. All rights reserved. 1 Beyond
More informationncounter TM Analysis System
ncounter TM Analysis System Molecules That Count TM www.nanostring.com Agenda NanoString Technologies History Introduction to the ncounter Analysis System CodeSet Design and Assay Principals System Performance
More informationComputer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015
Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a
More informationThe Avatar System TM Yields Biologically Relevant Results
Application Note The Avatar System TM Yields Biologically Relevant Results Liquid biopsies stand to revolutionize the cancer field, enabling early detection and noninvasive monitoring of tumors. In the
More informationNon-Invasive Array Based Screening for Cancer. Dr. Amit Kumar President and CEO CombiMatrix Corporation
Non-Invasive Array Based Screening for Cancer Dr. Amit Kumar President and CEO CombiMatrix Corporation www.combimatrix.com May 13, 2009 This presentation contains forward-looking statements within the
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationdeveloping new tools for diagnostics Join forces with IMGM Laboratories to make your mirna project a success
micrornas developing new tools for diagnostics Join forces with IMGM Laboratories to make your mirna project a success Dr. Carola Wagner IMGM Laboratories GmbH Martinsried, Germany qpcr 2009 Symposium
More informationTITLE: Total RNA Sequencing Analysis of DCIS Progressing to Invasive Breast Cancer.
AWARD NUMBER: W81XWH-14-1-0080 TITLE: Total RNA Sequencing Analysis of DCIS Progressing to Invasive Breast Cancer. PRINCIPAL INVESTIGATOR: Christopher B. Umbricht, MD, PhD CONTRACTING ORGANIZATION: Johns
More informationCellecta Overview. Started Operations in 2007 Headquarters: Mountain View, CA
Cellecta Overview Started Operations in 2007 Headquarters: Mountain View, CA Focus: Development of flexible, scalable, and broadly parallel genetic screening assays to expedite the discovery and characterization
More informationBiomarker development in the era of precision medicine. Bei Li, Interdisciplinary Technical Journal Club
Biomarker development in the era of precision medicine Bei Li, 23.08.2016 Interdisciplinary Technical Journal Club The top ten highest-grossing drugs in the United States help between 1 in 25 and 1 in
More informationThe role of noncoding RNA in thyroid cancer
Review Article The role of noncoding RNA in thyroid cancer Xinying Li, Zhiming Wang Department of General Surgery, Xiangya Hospital, Central South University, Xiangya Road 87, Changsha 410008, People s
More informationSmall RNA Sequencing. Project Workflow. Service Description. Sequencing Service Specification BGISEQ-500 SERVICE OVERVIEW SAMPLE PREPARATION
BGISEQ-500 SERVICE OVERVIEW Small RNA Sequencing Service Description Small RNAs are a type of non-coding RNA (ncrna) molecules that are less than 200nt in length. They are often involved in gene silencing
More informationIntroduction to Systems Biology of Cancer Lecture 2
Introduction to Systems Biology of Cancer Lecture 2 Gustavo Stolovitzky IBM Research Icahn School of Medicine at Mt Sinai DREAM Challenges High throughput measurements: The age of omics Systems Biology
More informationSupplementary Tables. Supplementary Figures
Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample
More informationmicrornas (mirna) and Biomarkers
micrornas (mirna) and Biomarkers Small RNAs Make Big Splash mirnas & Genome Function Biomarkers in Cancer Future Prospects Javed Khan M.D. National Cancer Institute EORTC-NCI-ASCO November 2007 The Human
More informationRNA- seq Introduc1on. Promises and pi7alls
RNA- seq Introduc1on Promises and pi7alls DNA is the same in all cells but which RNAs that is present is different in all cells There is a wide variety of different func1onal RNAs Which RNAs (and some1mes
More informationThe Biology and Genetics of Cells and Organisms The Biology of Cancer
The Biology and Genetics of Cells and Organisms The Biology of Cancer Mendel and Genetics How many distinct genes are present in the genomes of mammals? - 21,000 for human. - Genetic information is carried
More informationSUPPLEMENTARY INFORMATION
doi:.38/nature8975 SUPPLEMENTAL TEXT Unique association of HOTAIR with patient outcome To determine whether the expression of other HOX lincrnas in addition to HOTAIR can predict patient outcome, we measured
More informationNGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation
NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation Michael R. Rossi, PhD, FACMG Assistant Professor Division of Cancer Biology, Department of Radiation Oncology Department
More informationmicrorna Therapeutics Heading Towards the Clinic
GENReports: Market & Tech Analysis microrna Therapeutics Heading Towards the Clinic > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us Topic Introduction and Scope
More informationExtracellular Vesicle RNA isolation Kits
Extracellular Vesicle RNA isolation Kits Summary Section 4 Introduction 42 Exo-TotalRNA and TumorExo-TotalRNA isolation kits 43 Extracellular Vesicle RNA extraction kits Ordering information Products can
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationProkaryotes and eukaryotes alter gene expression in response to their changing environment
Chapter 18 Prokaryotes and eukaryotes alter gene expression in response to their changing environment In multicellular eukaryotes, gene expression regulates development and is responsible for differences
More informationApplications. in Oncology
Kewal K. Jain Applications of Biotechnology in Oncology Applications of Biotechnology in Oncology Applications of Biotechnology in Oncology Kewal K. Jain, MD, FRACS, FFPM Jain PharmaBiotech, Basel, Switzerland
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationDisruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017
Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From
More informationMicroRNAs, RNA Modifications, RNA Editing. Bora E. Baysal MD, PhD Oncology for Scientists Lecture Tue, Oct 17, 2017, 3:30 PM - 5:00 PM
MicroRNAs, RNA Modifications, RNA Editing Bora E. Baysal MD, PhD Oncology for Scientists Lecture Tue, Oct 17, 2017, 3:30 PM - 5:00 PM Expanding world of RNAs mrna, messenger RNA (~20,000) trna, transfer
More informationBreast cancer. Risk factors you cannot change include: Treatment Plan Selection. Inferring Transcriptional Module from Breast Cancer Profile Data
Breast cancer Inferring Transcriptional Module from Breast Cancer Profile Data Breast Cancer and Targeted Therapy Microarray Profile Data Inferring Transcriptional Module Methods CSC 177 Data Warehousing
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 20
More informationRNA SEQUENCING AND DATA ANALYSIS
RNA SEQUENCING AND DATA ANALYSIS Download slides and package http://odin.mdacc.tmc.edu/~rverhaak/package.zip http://odin.mdacc.tmc.edu/~rverhaak/rna-seqlecture.zip Overview Introduction into the topic
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationNot IN Our Genes - A Different Kind of Inheritance.! Christopher Phiel, Ph.D. University of Colorado Denver Mini-STEM School February 4, 2014
Not IN Our Genes - A Different Kind of Inheritance! Christopher Phiel, Ph.D. University of Colorado Denver Mini-STEM School February 4, 2014 Epigenetics in Mainstream Media Epigenetics *Current definition:
More informationSet the stage: Genomics technology. Jos Kleinjans Dept of Toxicogenomics Maastricht University, the Netherlands
Set the stage: Genomics technology Jos Kleinjans Dept of Toxicogenomics Maastricht University, the Netherlands Amendment to the latest consolidated version of the REACH legislation REACH Regulation 1907/2006:
More informationMost everyone in this room has been affected in one way or another by it, but what is it?
Most everyone in this room has been affected in one way or another by it, but what is it? All information is up to date and referenced to Sam Rhine s Genetic Update Conference, University of Nebraska &
More informationThe rat microrna body atlas: mirna identification and characterization
The rat microrna body atlas: mirna identification and characterization A Project of the HESI Genomics Committee Alison Harrill, Aaron Smith, and Raegan O Lone MicroRNAs: Tissue Specific Biomarkers mirna
More informationThe Cancer Genome Atlas & International Cancer Genome Consortium
The Cancer Genome Atlas & International Cancer Genome Consortium Session 3 Dr Jason Wong Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 31 st July 2014 1
More informationGene Regulation Part 2
Michael Cummings Chapter 9 Gene Regulation Part 2 David Reisman University of South Carolina Other topics in Chp 9 Part 2 Protein folding diseases Most diseases are caused by mutations in the DNA that
More informationRaymond Auerbach PhD Candidate, Yale University Gerstein and Snyder Labs August 30, 2012
Elucidating Transcriptional Regulation at Multiple Scales Using High-Throughput Sequencing, Data Integration, and Computational Methods Raymond Auerbach PhD Candidate, Yale University Gerstein and Snyder
More informationAnalysis of small RNAs from Drosophila Schneider cells using the Small RNA assay on the Agilent 2100 bioanalyzer. Application Note
Analysis of small RNAs from Drosophila Schneider cells using the Small RNA assay on the Agilent 2100 bioanalyzer Application Note Odile Sismeiro, Jean-Yves Coppée, Christophe Antoniewski, and Hélène Thomassin
More informationMODULE 3: TRANSCRIPTION PART II
MODULE 3: TRANSCRIPTION PART II Lesson Plan: Title S. CATHERINE SILVER KEY, CHIYEDZA SMALL Transcription Part II: What happens to the initial (premrna) transcript made by RNA pol II? Objectives Explain
More informationFounded in 2016 to develop life-changing therapies against debilitating aggressive cancers that have limited treatment options
Founded in 2016 to develop life-changing therapies against debilitating aggressive cancers that have limited treatment options Integrated platform technology for discovery of novel molecular targets and
More informationDNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA
DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA Maria Chimonidou 1, Areti Strati 1, Nikos Malamos 2, Vasilis Georgoulias
More informationIntroduction. Introduction
Introduction We are leveraging genome sequencing data from The Cancer Genome Atlas (TCGA) to more accurately define mutated and stable genes and dysregulated metabolic pathways in solid tumors. These efforts
More informationDiagnostic test Suggested website label Description Hospitals available
Diagnostic test Suggested website label Description Hospitals available Abbott Molecular Inc, PATHVYSION HER-2 DNA Probe Kit (FISH) PathVysion kit A diagnostic tool used to determine whether a particular
More informationNCRI Biomarkers & Imaging CSG Cell-free DNA workshop
NCRI Biomarkers & Imaging CSG Cell-free DNA workshop Workshop Report Christie Education Centre, Manchester 30th January 2014 Sponsored by Workshop summary 86 delegates from a variety of specialities attended
More informationTranscriptome Analysis
Transcriptome Analysis Data Preprocessing Sample Preparation Illumina Sequencing Demultiplexing Raw FastQ Reference Genome (fasta) Reference Annotation (GTF) Reference Genome Analysis Tophat Accepted hits
More informationBiopharma and HTG Molecular Diagnostics Sample Sensitivity Data
Biopharma and HTG Molecular Diagnostics Sample Sensitivity Data Accelerating your success. Working in harmony with next-generation sequencing (NGS) platforms, HTG s patented chemistry, multiplexed assays
More informationMicroRNAs: a new source of biomarkers in radiation response. Simone Moertl, Helmholtz Centre Munich
MicroRNAs: a new source of biomarkers in radiation response Simone Moertl, Helmholtz Centre Munich The RNA World mrna rrna coding snorna trna scarna RNA snrna noncoding lincrna rasirna RNAi anti-sense
More informationLiposarcoma*Genome*Project*
LiposarcomaGenomeProject July2015! Submittedby: JohnMullen,MD EdwinChoy,MD,PhD GregoryCote,MD,PhD G.PeturNielsen,MD BradBernstein,MD,PhD Liposarcoma Background Liposarcoma is the most common soft tissue
More informationmirna Whole Transcriptome Assay
mirna Whole Transcriptome Assay HTG EdgeSeq mirna Whole Transciptome Assay The HTG EdgeSeq mirna Whole Transcriptome Assay (WTA) is a next generation sequencing (NGS) application that measures the expression
More informationDecipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com
More informationShould novel molecular therapies replace old knowledge of clinical tumor biology?
Should novel molecular therapies replace old knowledge of clinical tumor biology? Danai Daliani, M.D. Director, 1 st Oncology Clinic Euroclinic of Athens Cancer Treatments Localized disease Surgery XRT
More informationSurvey Results Q1. How would you best describe your organization?
Survey Results Q1. How would you best describe your organization? Q2. How high would you rate the priority of Circulating Tumor Cells in you organization? Q3. What do you think is the biggest challenge
More informationBIOLOGY OF CANCER. Definition: Cancer. Why is it Important to Understand the Biology of Cancer? Regulation of the Cell Cycle 2/13/2015
BIOLOGY OF CANCER Why is it Important to Understand the Biology of Cancer? Cynthia Smith, RN, BA, MSN, AOCN Oncology Clinical Nurse Specialist Harrison Medical Center Definition: Cancer Regulation of the
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. Pan-cancer analysis of global and local DNA methylation variation a) Variations in global DNA methylation are shown as measured by averaging the genome-wide
More informationCOXEN FOR PREOPERATIVE BLADDER CANCER CHEMOTHERAPY - IN DEVELOPMENT. Slide support from Dan Theodorescu
COXEN FOR PREOPERATIVE BLADDER CANCER CHEMOTHERAPY - IN DEVELOPMENT Slide support from Dan Theodorescu Bladder Cancer: 0 In need of transformative change Kidney cancer: 7 newly approved drugs, more on
More informationBiochemistry of Cancer and Tumor Markers
Biochemistry of Cancer and Tumor Markers The term cancer applies to a group of diseases in which cells grow abnormally and form a malignant tumor. It is a long term multistage genetic process. The first
More informationNon-Profit Startup Paradigm Launches Cancer Panel Based on DNA, RNA Sequencing
Non-Profit Startup Paradigm Launches Cancer Panel Based on DNA, RNA Sequencing April 11, 2014 By Tony Fong Non-profit diagnostics outfit Paradigm last month joined a growing list of entrants in the clinical
More informationPROTEIN SYNTHESIS. It is known today that GENES direct the production of the proteins that determine the phonotypical characteristics of organisms.
PROTEIN SYNTHESIS It is known today that GENES direct the production of the proteins that determine the phonotypical characteristics of organisms.» GENES = a sequence of nucleotides in DNA that performs
More informationWhat causes cancer? Physical factors (radiation, ionization) Chemical factors (carcinogens) Biological factors (virus, bacteria, parasite)
Oncogenes What causes cancer? Chemical factors (carcinogens) Physical factors (radiation, ionization) Biological factors (virus, bacteria, parasite) DNA Mutation or damage Oncogenes Tumor suppressor genes
More informationEnterprise Interest Thermo Fisher Scientific / Employee
Enterprise Interest Thermo Fisher Scientific / Employee A next-generation sequencing assay to estimate tumor mutation load from FFPE research samples Fiona Hyland. Director of R&D, Bioinformatics Clinical
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationIntegrated platform for liquid biopsy-based personalized cancer medicine
Integrated platform for liquid biopsy-based personalized cancer medicine Dr. Bernhard Polzer Fraunhofer ITEM-Regensburg Personalized Tumor Therapy Personalized cancer therapy Primary tumor single tumor
More informationNext Generation Cancer Diagnostics For First Time Right Therapy Choice. Anja van de Stolpe
Next Generation Cancer Diagnostics For First Time Right Therapy Choice Anja van de Stolpe Paradigm shift in cancer treatment towards personalized treatment Chemotherapy for all therapy targeting cancer
More informationTrinity: Transcriptome Assembly for Genetic and Functional Analysis of Cancer [U24]
Trinity: Transcriptome Assembly for Genetic and Functional Analysis of Cancer [U24] ITCR meeting, June 2016 The Cancer Transcriptome A window into the (expressed) genetic and epigenetic state of a tumor
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationComprehensive Tumor Profiling of Immune Response and Systems Biology. HTG EdgeSeq Immuno-Oncology Assay. HTG EdgeSeq Oncology Biomarker Panel
Comprehensive Tumor Profiling of Immune Response and Systems Biology HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Oncology Biomarker Panel A new frontier in the research of cancer therapeutics HTG provides
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 28
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More information1. Epistasis Analysis Reveals Distinct Roles of Non-homologous End Joining Factors in Human HAP1 Cells Mengtan Xing, NTNU
Posters you find at the NORBIS meeting 1. Epistasis Analysis Reveals Distinct Roles of Non-homologous End Joining Factors in Human HAP1 Cells Mengtan Xing, NTNU 2. Copy Number Variation detection tool
More informationStudy Finds Lung Cancer Subtype Test from UNC, Startup GeneCentric to be Accurate, Reproducible
Study Finds Lung Cancer Subtype Test from UNC, Startup GeneCentric to be Accurate, Reproducible May 30, 2013 By Ben Butkus A team led by clinical researchers from the University of North Carolina, Chapel
More information